Articolo su Invito

Archivio di Ortopedia e Reumatologia

, Volume 119, Issue 3, pp 28-30

First online:

L’aderenza alle terapie per l’osteoporosi: l’esempio dei bisfosfonati

  • S. CasariAffiliated withU.O.C.Day Hospital di Reumatologia, Istituto Ortopedico G.Pini
  • , L. SinigagliaAffiliated withU.O.C.Day Hospital di Reumatologia, Istituto Ortopedico G.Pini

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Adherence to osteoporosis therapy: the example of bisphosphonates

Abstract

Bisphosphonates are the most potent and effective inhibitors of bone resorption in clinical use, with good efficacy and tolerability in reducing fracture risk, in increasing bone mineral density and in reducing biochemical markers of bone turnover. Clinical trials indicate that bisphosphonates can reduce the incidence of fractures related to postmenopausal osteoporosis but adherence to bisphosphonate therapy remains suboptimal. Long-term adherence with bisphosphonates is required for optimal and sustained therapeutic benefits in postmenopausal osteoporosis. Simplifying dosing by reducing the frequency and/or number of administrations is an often-used strategy for enhancing adherence, especially with new compounds with high anti-resorptive potency and favourable bone-binding properties